North Macedonia vs South-eastern Asia: Percentage of bloodstream infection due to Escherichia coli resistant
North Macedonia
60.0%
in 2022
South-eastern Asia
50.0%
in 2022
North Macedonia rank
11th
South-eastern Asia rank
8th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- North Macedonia
- South-eastern Asia
How they compare
North Macedonia currently reports 60.0% against 50.0% in South-eastern Asia, a difference of 10.0%.
That makes North Macedonia's figure about 1.2 times South-eastern Asia's.
Across all 7 years both countries report, North Macedonia has been ahead every year.
North Macedonia ranks 11th and South-eastern Asia ranks 8th of 50 countries.
North Macedonia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | North Macedonia | South-eastern Asia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 72.0% | 46.2% | 25.8% | North Macedonia |
| 2020s | 65.6% | 46.4% | 19.3% | North Macedonia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, North Macedonia or South-eastern Asia?
- North Macedonia, at 60.0% against 50.0% in South-eastern Asia as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between North Macedonia and South-eastern Asia?
- 10.0%, with North Macedonia ahead.
- How many years of comparable data are there for North Macedonia and South-eastern Asia?
- 7 years are reported by both, from 2016 to 2022.
- How do North Macedonia and South-eastern Asia rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- North Macedonia ranks 11th and South-eastern Asia ranks 8th of 50 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.